Antitumor activity of an anti‐CD98 antibody

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0215|137|3|710-720

ISSN： 0020-7136

Source： INTERNATIONAL JOURNAL OF CANCER, Vol.137, Iss.3, 2015-08, pp. : 710-720

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The combination of milatuzumab, a humanized anti‐CD74 antibody, and veltuzumab, a humanized anti‐CD20 antibody, demonstrates activity in patients with relapsed and refractory B‐cell non‐Hodgkin lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 5, 2015-06 ,pp. : 701-710

John Wiley & Sons Inc

Access to resources Recommend Favorite

NKG2A is a marker for acquisition of regulatory function by human CD8+ T cells activated with anti‐CD3 antibody

By  

EUROPEAN JOURNAL OF IMMUNOLOGY, Vol. 41, Iss. 7, 2011-07 ,pp. : 1832-1842

John Wiley & Sons Inc

Access to resources Recommend Favorite

Fetal/neonatal alloimmune thrombocytopenia due to anti‐CD36 antibodies: antibody evaluations by CD36‐transfected cell lines

By  

TRANSFUSION, Vol. 58, Iss. 1, 2018-01 ,pp. : 189-195

John Wiley & Sons Inc

Access to resources Recommend Favorite

Immunotherapy with the trifunctional anti‐CD20 x anti‐CD3 antibody FBTA05 (Lymphomun) in paediatric high‐risk patients with recurrent CD20‐positive B cell malignancies

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 1, 2015-04 ,pp. : 90-102

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of CNS Lymphoma with the Anti-CD20 Antibody Rituximab: Experience with Two Cases and Review of the Literature

By  

Oncology Research and Treatment, Vol. 26, Iss. 4, 2003-09 ,pp. : 351-354

Karger

Access to resources Recommend Favorite